Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Mallinckrodt (MNK) to complete Phase 4 study of HP Acthar Gel in patients with multiple sclerosis in December 2018

Source Link:: https://clinicaltrials.gov/ct2/show/NCT02446886?term=mallinckrodt&recr=Open&no_unk=Y&rank=24

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

MNK

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details The primary objective of this study is to determine if monthly pulse doses of a three-day course ACTH (H.P. Acthar®) is more effective at recovering myelin at 12 months, as measured by myelin water fraction (MWF), in new multiple sclerosis lesions as compared to one course of treatment.

https://clinicaltria...

Additional Relevant Details Jan 2017 Update: It was initially expected to complete in August 2016, new timeline set for Dec 2018.

https://clinicaltria...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Feb 05, 2019

Occurred Source:

https://www.prnewswire.com/news-releases/mallinckrodt-provides-update-on-phase-4-data-hp-acthar-gel-repository-corticotropin-injection-clinical-trial-in-patients-with-rheumatoid-arthritis-ra-300789523.html

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 4, Hp Acthar Gel, Multiple Sclerosis, Repository Corticotropin Injection, Adrenocorticotropic Hormone, Remyelination